Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer

NCT05172700 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Lymphocytic, Small
Lymphoma, Mantle-Cell
Waldenstrom Macroglobulinemia
Ritcher's Transformation, Syndrome

Interventions

DRUG: Pirtobrutinib

Sponsor

Loxo Oncology, Inc.